Skip Nav Destination
Issues
1 March 2018
-
Cover Image
Cover Image
ABOUT THE COVER
Internalization of the antibody against a tumor antigen is one of the key features in developing an antibody-drug conjugate (ADC) therapeutic. Bhakta and colleagues identify GFRA1 as an excellent luminal A breast cancer ADC target. The image depicts the internalization of anti-GFRA1 antibody-Alexa488 conjugate (green) upon binding to HEK293 cells expressing GFRA1 protein. It's co-localization (yellow) with LAMP2, a late endosomal/lysosmal marker (red) is observed. Image Courtesy: Coenraad Kuijl. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
Paola Magnaghi; Barbara Salom; Liviana Cozzi; Nadia Amboldi; Dario Ballinari; Elena Tamborini; Fabio Gasparri; Alessia Montagnoli; Laura Raddrizzani; Alessio Somaschini; Roberta Bosotti; Christian Orrenius; Fabio Bozzi; Silvana Pilotti; Arturo Galvani; Josh Sommer; Silvia Stacchiotti; Antonella Isacchi
Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Noelia Puente-Moncada; Paula Costales; Isaac Antolín; Luz-Elena Núñez; Patricia Oro; Maria Ana Hermosilla; Jhudit Pérez-Escuredo; Nicolás Ríos-Lombardía; Ana M. Sanchez-Sanchez; Elisa Luño; Carmen Rodríguez; Vanesa Martín; Francisco Morís
Large Molecule Therapeutics
Author Choice
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
Sunil Bhakta; Lisa M. Crocker; Yvonne Chen; Meredith Hazen; Melissa M. Schutten; Dongwei Li; Coenraad Kuijl; Rachana Ohri; Fiona Zhong; Kirsten A. Poon; Mary Ann T. Go; Eric Cheng; Robert Piskol; Ron Firestein; Aimee Fourie-O'Donohue; Katherine R. Kozak; Helga Raab; Jo-Anne Hongo; Deepak Sampath; Mark S. Dennis; Richard H. Scheller; Paul Polakis; Jagath R. Junutula
Author Choice
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
Michael L. Miller; Manami Shizuka; Alan Wilhelm; Paulin Salomon; Emily E. Reid; Leanne Lanieri; Surina Sikka; Erin K. Maloney; Lauren Harvey; Qifeng Qiu; Katie E. Archer; Chen Bai; Dilrukshi Vitharana; Luke Harris; Rajeeva Singh; Jose F. Ponte; Nicholas C. Yoder; Yelena Kovtun; Katharine C. Lai; Olga Ab; Jan Pinkas; Thomas A. Keating; Ravi V.J. Chari
Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin–Antibody Conjugate
Tadanobu Nagaya; Alexander P. Gorka; Roger R. Nani; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Peter L. Choyke; Martin J. Schnermann; Hisataka Kobayashi
Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri; Isabella C. Glitza; Sonia L. Betancourt Cuellar; Vivek Subbiah; Siqing Fu; Apostolia M. Tsimberidou; Jennifer J. Wheler; David S. Hong; Aung Naing; Gerald S. Falchook; Michelle A. Fanale; Maria E. Cabanillas; Filip Janku
Cancer Biology and Translational Studies
Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors
Apurva K. Srivastava; Melinda G. Hollingshead; Jeevan Prasaad Govindharajulu; Joseph M. Covey; Dane Liston; Melanie A. Simpson; James O. Peggins; Donald P. Bottaro; John J. Wright; Robert J. Kinders; James H. Doroshow; Ralph E. Parchment
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma
Conor E. Steuer; Christopher C. Griffith; Sreenivas Nannapaneni; Mihir R. Patel; Yuan Liu; Kelly R. Magliocca; Mark W. El-Deiry; Cynthia Cohen; Taofeek K. Owonikoko; Dong M. Shin; Zhuo G. Chen; Nabil F. Saba
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds
